Evaluation of benazepril in cats with heart disease in a prospective, randomized, blinded, placebo‐controlled clinical trial

Abstract Background Heart disease is an important cause of morbidity and mortality in cats, but there is limited evidence of the benefit of any medication. Hypothesis The angiotensin‐converting enzyme inhibitor benazepril would delay the time to treatment failure in cats with heart disease of variou...

Full description

Bibliographic Details

Main Authors:	Jonathan N. King, Mike Martin, Valérie Chetboul, Luca Ferasin, Anne T. French, Günther Strehlau, Wolfgang Seewald, Sarah G. W. Smith, Simon T. Swift, Susan L. Roberts, Andrea M. Harvey, Christopher J. L. Little, Sarah M. A. Caney, Kerry E. Simpson, Andrew H. Sparkes, Eleanor J. Mardell, Eric Bomassi, Claude Muller, John P. Sauvage, Armelle Diquélou, Matthias A. Schneider, Laurence J. Brown, David D. Clarke, Jean‐Francois Rousselot
Format:	Artigo
Language:	Inglês
Published:	Oxford University Press 2019-11-01
Series:	Journal of Veterinary Internal Medicine
Subjects:	ACE inhibitor survival treatment failure
Online Access:	https://doi.org/10.1111/jvim.15572
Tags:	Add Tag No Tags, Be the first to tag this record!